Work

ARIEL 2/3: An integrated clinical trial program to assess activity of rucaparib in ovarian cancer and to identify tumor molecular characteristics predictive of response.

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.tps5619

Authors: Elizabeth M. Swisher, Iain A. McNeish, Robert L. Coleman, James Brenton, Scott H. Kaufmann, Andrew R. Allen, Mitch Raponi, Heidi Giordano, Lara Maloney, Jeff Isaacson, Jonathan A. Ledermann

Institutions: University of Washington, University of Glasgow, The University of Texas MD Anderson Cancer Center, University of Cambridge, Mayo Clinic, Clovis Oncology (United States), University College London

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2598863230

Cites:

Cited by: 12

Related to: 10